Recently, the company announced a collaboration with the Charcot–Marie–Tooth Association ... first-in-class treatment for peripheral neuropathies, which affect many millions of people ...
Mitochondria In Motion Inc. has identified new N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives acting as mitofusin activators and reported to be useful for the treatment of Alzheimer’s, ...
SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder that’s both progressive and incurable. But now, nerve specialists ...
“We need to develop a treatment that can improve quality of life and neurological function for those with this difficult illness.” Saint Louis University currently is enrolling patients in a phase III ...
The SynGAP Research Fund 501(c)(3) has awarded a pair of grants to Dr. Clement Chow, a geneticist and Associate Professor in the Department of Human Genetics at the University of Utah. These grants ...
They have focused on the pathogenesis of inherited demyelinating neuropathies, and have developed and characterized multiple mouse models of Charcot-Marie-Tooth (CMT) neuropathies. By introducing ...
Treatment with CKD-510 restored the shortened ... including the application to neurodegenerative diseases such as Charcot-Marie-Tooth disease (CMT) 1, 2. The axonal transport of intracellular ...
For informational purposes only. Consult a medical professional for advice. Source: Focus Medica. A group of inherited disorders which cause nerve damage mostly in arms and legs. Weakness in limbs ...
Actio is advancing two lead rare disease programs with first-in-class potential for the treatment of Charcot-Marie-Tooth Disease, Type 2C (CMT2C) and genetic epilepsy. The CMT2C program is ...
Ask your doctor if you’re not sure if your anxiety will affect your driving. You must tell DVLA if your aortic aneurysm is 6 centimetres or more in diameter despite treatment. You must not drive if ...